Cervical cancer is noted for being preventable, yet it continues to be one of the leading causes of cancer-related death among women globally. Each year, the World Health Organization (WHO) reports that over 350,000 women succumb to cervical cancer, with around 90% of these deaths occurring in low- and middle-income countries. In these regions, access to routine cervical cancer screening is often severely restricted, leaving women vulnerable. The primary cause of cervical cancer is persistent infection with high-risk HPV types. While vaccination campaigns aim to immunize younger populations and reduce HPV infections, many at-risk older women remain unvaccinated. Therefore, reliable and regular screening is crucial for early detection and effective treatment.

Maria Barra, a bioengineering graduate student at Rice University and the first author of the study, emphasized the urgency of this test. Barra noted the ongoing tragedy of cervical cancer fatalities despite it being almost entirely preventable. The team’s objective was to create a testing method that meets three essential criteria: it must deliver accurate results to guide treatment, be rapid enough for use within a clinical setting, and be cost-effective to allow for wide-scale deployment. The newly developed assay achieves all these requirements.

The WHO promotes HPV DNA testing as the gold standard for cervical cancer screenings, but many existing tests necessitate expensive laboratory equipment and trained technicians. As a result, these requirements pose significant barriers to implementation in less affluent areas. A common issue encountered in current screening methodologies is that results can take several days or weeks to process, typically requiring patients to return for follow-up appointments. This delay is particularly problematic in remote healthcare settings, where access to services is limited and patients may be unable to revisit for treatment. The introduction of a faster, lab-independent test that delivers results on the same day is a potentially life-saving solution.

The new HPV testing method utilizes loop-mediated isothermal amplification (LAMP), which simplifies DNA detection by operating at a single temperature. By eliminating the need for complex DNA extraction processes typically seen in many tests, this testing method streamlines the overall procedure. Instead, the LAMP approach begins with the collection of a swab sample, which is chemically lysed and directly combined with the LAMP reagents for incubation in a portable heater for about 45 minutes, followed by fluorescence reading to determine results.

This test specifically identifies three of the most high-risk HPV types, namely HPV16, HPV18, and HPV45, which collectively account for approximately 75% of cervical cancer cases. Moreover, a cellular control mechanism is incorporated within the test, verifying that samples have been collected correctly, which is crucial for ensuring test accuracy and reliability.

Clinical trials have yielded impressive results, showing a 100% agreement with reference standards in 38 samples collected from Houston, Texas, and a 93% agreement based on 191 samples from the Mozambican capital, Maputo. The anticipated costs of conducting this test are projected to be under $8 per test. Additionally, the device operates on batteries, making it well-suited for clinics that may lack stable electricity sources.

Cesaltina Lorenzoni, a prominent figure in Mozambique’s healthcare landscape and the head of the National Cancer Control Program, has recognized the potential impact of this innovative screening technology. Lorenzoni stated that high rates of cancer-related mortality are often linked to extended delays in diagnosis and limited access to early treatment options. Implementing point-of-care technologies that facilitate immediate cancer identification and treatment guidance during a single visit could significantly improve patient outcomes in Maputo’s clinical environments. The favorable performance of this HPV assay in local clinical settings presents an exciting opportunity for improving women’s health throughout the region.

In line with the WHO’s ambitious strategy to screen 70% of women worldwide by 2030, achieving this target necessitates the screening of millions of women across various global settings that typically lack advanced laboratory equipment. The introduction of the LAMP assay is a major step towards realizing this goal by reducing the need for costly laboratory instruments, minimizing unnecessary sample handling, and delivering timely, accurate results.

Moreover, a key benefit of the new testing approach is its facilitation of “screen-and-treat” paradigms. This process allows for immediate treatment upon receiving positive test results, thereby minimizing delays and preventing patients from falling through the cracks due to lost appointments. This innovation has the potential to transform cervical cancer intervention narratives in resource-limited settings.

Looking toward the future, the research team aims to expand the test to include an even broader range of high-risk HPV types. Additionally, they are exploring the development of lyophilized, freeze-dried reagents that do not necessitate refrigeration, further enhancing the test’s practicality in rural and under-resourced communities. To ensure that the device’s design perfectly aligns with the needs of healthcare providers, usability studies with frontline health workers will be conducted prior to larger-scale implementation.

In moving towards a world where cervical cancer can be entirely eradicated, Richards-Kortum, a professor of bioengineering and co-director of Rice360 Institute for Global Health Technologies, expressed the team’s vision. By creating a comprehensive, field-ready testing kit suitable for use in various community clinics, it may become possible to establish same-day screening and treatment paradigms. Such changes would mark a dramatic shift in global health and have the potential to save lives across populations currently facing significant barriers to adequate healthcare services.

The research carried out was supported by critical partnerships and received essential approvals from multiple institutional review boards, including those at MD Anderson, Harris Health, Rice University, and Mozambique’s National Bioethics Committee. All participants in the study were fully informed and consented, ensuring the ethical integrity of the research process. Furthermore, financial support for the investigation was provided by the National Institutes of Health.

Subject of Research: A rapid, affordable HPV test for cervical cancer screening
Article Title: One-hour extraction-free loop-mediated isothermal amplification HPV DNA assay for point-of-care testing in Maputo, Mozambique
News Publication Date: 7-Aug-2025
Web References: Nature Communications DOI
References: None available
Image Credits: Credit: Rice University

Keywords

Bioengineering, Biomedical engineering, Medical technology, Public health

HPV infections, especially with high-risk genotypes, are the principal cause of cervical cancer, one of the most common cancers among women worldwide and a leading cause of cancer mortality in low- and middle-income countries. Existing HPV testing methodologies, such as polymerase chain reaction (PCR)-based assays, although highly sensitive, often demand complex laboratory infrastructure, skilled personnel, and lengthy processing times, making them impractical for regions with limited healthcare resources. This challenge has motivated researchers to develop novel molecular diagnostic tools capable of delivering rapid, accurate results at the point of care, a need paramount in enhancing cervical cancer screening coverage and effectiveness.

The newly developed LAMP-based assay stands out due to its extraction-free approach, which eliminates the traditionally cumbersome nucleic acid purification step. Conventional HPV DNA detection protocols often entail elaborate specimen processing to isolate viral DNA, a bottleneck that lengthens testing time and requires laboratory facilities. The LAMP assay bypasses this necessity by directly using the patient’s sample, thereby substantially reducing the complexity, cost, and turnaround time of testing. This simplification is critical for deployment in community screening programs, where streamlining workflow and minimizing technical demands can translate to broader accessibility.

LAMP itself is a nucleic acid amplification technique renowned for its rapidity, high specificity, and constant-temperature operation, requiring only a simple heating device rather than sophisticated thermocyclers. By designing primers that distinctly target HPV genomic sequences, the assay amplifies viral DNA with remarkable efficiency, observable through real-time fluorescence or colorimetric change. Coupled with the omission of DNA extraction, this method achieves a one-hour workflow from sample collection to result readout, fulfilling an indispensable criterion for point-of-care diagnostics.

Testing this platform in Maputo involved collaboration with local health authorities and deployment within real-world clinical environments, ensuring that the assay’s performance metrics reflect practical conditions rather than ideal laboratory settings. The researchers enrolled women undergoing routine cervical cancer screening, collecting cervical specimens that underwent parallel testing by standard laboratory PCR-based methods and the LAMP assay. Comparative analyses demonstrated that the LAMP platform not only matched the sensitivity and specificity benchmarks set by conventional assays but did so with dramatically faster turnaround, underscoring its practical utility.

Crucially, the assay showed robust detection of high-risk HPV genotypes associated with oncogenic transformation, enabling clinicians to stratify patients’ risk profiles rapidly. Early identification facilitates timely referral for follow-up diagnostic procedures and treatment interventions, which are pivotal in preventing progression to invasive cervical cancer. By expanding access to reliable and timely HPV screening, especially in regions where women face significant barriers to healthcare, the assay promises to make a tangible impact on public health outcomes.

The simplified workflow also reduces operational costs, a significant barrier for many screening programs reliant on molecular testing. The elimination of DNA extraction consumables and equipment, combined with room-temperature-stable reagents, offers logistical advantages ideal for deployment in resource-limited clinics and mobile health units. This flexibility supports integration into existing healthcare frameworks without the necessity for capital investment in laboratory infrastructure, training, or cold chain maintenance.

Given the global disparities in cervical cancer incidence and mortality, innovations like this LAMP assay are critical for achieving equitable health outcomes. According to the World Health Organization, more than 85% of cervical cancer deaths occur in low- and middle-income countries where access to screening remains severely restricted. Point-of-care tests that balance accuracy, affordability, and rapid turnaround can transform screening paradigms, enabling population-wide HPV testing programs better aligned with local infrastructure and community needs.

Beyond detection, this assay’s rapid results facilitate same-visit counseling and management decisions, a feature particularly valuable in settings where patients may have difficulty returning for follow-up visits. Immediate communication of HPV status can improve patient engagement and adherence to recommended care pathways, enhancing the overall effectiveness of screening programs. The ability to conduct HPV testing and initiate triage or treatment within a single encounter embodies a critical step toward integrated, patient-centered care.

The scalability of the LAMP platform also opens doors to broader applications in infectious disease diagnostics. Similar extraction-free nucleic acid amplification assays could be adapted for detecting other pathogens, particularly in outbreak scenarios or remote settings where current molecular diagnostics are impractical. This versatility may catalyze a new generation of decentralized testing solutions, democratizing access to molecular diagnostics beyond traditional laboratory confines.

While the results from Maputo are encouraging, the researchers highlight the need for further validation across diverse populations and integration with screening programs of varying epidemiological profiles. Consideration of factors such as varying HPV genotype distributions and concurrent infections is important to ensure sustained assay performance across geographies. Future development may also explore multiplexing capabilities to simultaneously detect multiple HPV types or other sexually transmitted infections.

Safety and user-friendliness were central to the assay design, ensuring that operators with minimal technical training could perform the test reliably. The protocol was optimized to minimize contamination risk and incorporate closed-tube detection methods, preventing amplicon carryover and resultant false positives. These features increase the test’s suitability for field deployment, reinforcing its role as a practical, scalable solution for cervical cancer screening.

The commercial and public health implications of this advance are substantial. By enabling low-cost, high-throughput HPV screening at the point of care, the assay holds promise to accelerate progress toward global cervical cancer elimination goals outlined by international public health agencies. Specifically, increasing screening coverage and linking positive cases to timely treatment can reduce cervical cancer incidence and mortality substantially over the coming decades.

Moreover, the assay empowers community health workers and clinics to localize cervical cancer prevention efforts, fostering greater community engagement and health education. By transforming cervical cancer screening from a complex laboratory-dependent process into a rapid, on-site test, this innovation bridges a critical gap that has historically hindered screening uptake and effectiveness in underserved regions.

This work exemplifies the growing trend of leveraging nucleic acid amplification technologies in simplified, portable formats for enhancing diagnostic reach. As such platforms mature and become widely accessible, they may redefine the landscape of infectious disease control and cancer screening, especially in the Global South. The convergence of innovation, accessibility, and real-world applicability embodied by this assay represents a milestone toward more equitable healthcare delivery.

In conclusion, the one-hour extraction-free LAMP-based HPV DNA assay represents a paradigm shift in cervical cancer screening technology. Its combination of speed, sensitivity, operational simplicity, and affordability directly addresses the long-standing challenges of molecular HPV testing in resource-constrained settings. As demonstrated in Mozambique, this tool offers a path to more effective, decentralized cervical cancer prevention, with potential ripple effects across diverse health domains. Continued research, development, and policy support will be vital to realizing its full impact globally.

Subject of Research: Human papillomavirus (HPV) DNA detection for cervical cancer screening using a rapid, extraction-free loop-mediated isothermal amplification (LAMP) assay.

Article Title: One-hour extraction-free loop-mediated isothermal amplification HPV DNA assay for point-of-care testing in Maputo, Mozambique.

Article References:
Barra, M.J., Wilkinson, A.F., Ma, A.E. et al. One-hour extraction-free loop-mediated isothermal amplification HPV DNA assay for point-of-care testing in Maputo, Mozambique. Nat Commun 16, 7295 (2025). https://doi.org/10.1038/s41467-025-62454-x

Image Credits: AI Generated